U.S. Metals and Mining Stock News

Four Corners Property Trust (FCPT) has combined an upsized credit facility with its largest acquisition to date, the Mission Pet Health portfolio, giving investors fresh information on both balance sheet structure and portfolio mix. See our latest analysis for Four Corners Property Trust. At a share price of $26.33, Four Corners Property Trust has recorded a 13.30% year to date share price return. The 1 year total shareholder return of 8.91% sits alongside multi year total shareholder returns...

Global markets are wrestling with mixed inflation signals, shifting rate expectations and higher energy costs. That backdrop keeps investors focused on assets that can potentially benefit as digital infrastructure and new transaction systems evolve. The Top Cryptocurrency and Blockchain Stocks screener filters this wide universe into a more manageable starting list based on clear, transparent criteria. That helps you focus on businesses linked to crypto and blockchain themes without having to...

Murphy Oil previously announced it was expected to report higher year-over-year earnings and revenues for the June 2026 quarter, with the earnings release scheduled for August 5 and analyst models indicating a likely earnings beat based on an Earnings ESP of 0.25% and a Zacks Rank of 3. An interesting angle for investors is Murphy Oil’s consistent record of surpassing consensus EPS estimates in each of the last four quarters, which has fueled confidence in the company’s upcoming results...

Bicara Therapeutics recently appointed Jeremy Bender, Ph.D., MBA, former CEO of Day One Biopharmaceuticals, and ex-Genentech oncology leader Christy Oliger to its Board of Directors, while Kiran Mazumdar-Shaw retired from the board. The additions bring deep experience in oncology drug launches, large-scale portfolio management and major biotech M&A, potentially influencing how Bicara approaches late-stage development and commercialization decisions. Next, we’ll examine how adding experienced...

Globus Medical (GMED) stock drew renewed attention after its recent trading move, with the price closing at $81.42. Investors are now reassessing how its business profile and valuation stack up. See our latest analysis for Globus Medical. That latest move sits within a mixed picture. The 7 day share price return of 7.84% contrasts with a 30 day share price decline of 3% and a 90 day share price decline of 9.71%, while the 1 year total shareholder return of 52.33% points to stronger long run...

Consumer discretionary stocks sit right in the crosshairs of the latest US data, with slower 1.5% GDP growth in Q2, firm 3.3% core inflation, and solid 2.1% personal spending all pulling in different directions. That mix can reward companies with strong balance sheets and clear demand, while putting pressure on weaker business models. This article focuses on three consumer discretionary stocks from our screener that appear positively exposed to these trends. You will see how each one could...

After a strong three year run for Invesco stock, the valuation picture is not one sided. The intrinsic value estimate from the Excess Returns model points to meaningful upside relative to the share price, while the broader checks and market multiples suggest the stock is closer to fairly priced. Invesco has returned 96.7% over the past three years, which puts extra focus on whether the current price still offers an attractive entry level. The key support for the valuation is the market's...

Photronics stock has more than doubled over the past five years, yet its current valuation sends mixed signals. The Discounted Cash Flow (DCF) intrinsic value estimate points to the shares trading at a premium, while market multiples suggest the stock still screens as undervalued. Photronics has returned 104.8% over five years, which puts more attention on whether the current price builds in much of that progress. Expectations for continued demand in its niche of semiconductor manufacturing...

OPENLANE (OPLN) drew fresh attention after being highlighted alongside General Motors as an Auto Tires Trucks sector stock that has outperformed its group this year and currently carries a Zacks Rank of #2. See our latest analysis for OPENLANE. At a recent share price of US$40.44, OPENLANE has posted a strong 90 day share price return of 28.63% and a year to date share price return of 38.45%, while its 1 year total shareholder return of 64.06% and 3 year total shareholder return of about 2.6x...

Ashland walked into this earnings season with a stock that had quietly climbed over the past quarter, yet the initial reaction today is a mild pullback of about 1%. That muted move masks a quarter that puts profit quality in the spotlight. Adjusted earnings per share reached US$1.02 on revenue of US$497m, while free cash flow came in at US$103m with conversion above 90%. For a specialty chemicals business in which cash generation and margin resilience matter more than headline growth, this...

VICI Properties stock has drifted lower over the past year even as Simply Wall St's Discounted Cash Flow (DCF) intrinsic value estimate and traditional multiples both point to the shares trading at a discount to their assessed worth. Over the past 5 years VICI Properties has delivered a total return of 17.9%, which is positive but not especially strong for a REIT over that timeframe. The key support for the valuation is the cash flow profile from long term leases. The main risk is that...

AI infrastructure and semiconductor stocks have been under heavy selling pressure after Situational Awareness, Leopold Aschenbrenner’s hedge fund, began unwinding leveraged trades and facing margin calls. Forced liquidations in both public and private AI holdings are rippling through the market, which can quickly shift attention back to companies with steadier balance sheets, reliable dividends, and calmer price moves. This article looks at 3 stocks from a Defensive Value Stocks screener that...

Waystar Holding stock has declined 31.2% over the past year, yet the current checks send a mixed message on value as a Discounted Cash Flow (DCF) intrinsic value estimate points to upside while traditional market multiples lean the other way. The share price is down 31.2% over the last 12 months. This puts renewed attention on whether recent weakness has already priced in investor concerns. Growing adoption of Waystar Holding's healthcare payment software and recognition for its connected...

Stride, Inc. recently reported preliminary results for the fiscal year ended June 30, 2026, expecting revenue of US$2.52 billion and net income of US$338.2 million, alongside a leadership transition that saw long-time board member Robert Knowling become CEO and Steven Fink assume the role of Chair. The combination of higher expected revenue and profits with an experienced insider stepping into the CEO role could influence how investors assess the company’s operational focus and governance...

Royal Gold has delivered a strong share price gain over the past three years, yet the current valuation picture is more mixed, with the intrinsic value estimate based on a Discounted Cash Flow (DCF) model suggesting the stock trades at a discount while market based multiples look closer to fair value. Royal Gold has returned about 79.5% over three years, which puts more focus on whether the current price still leaves room for attractive long term returns. The company’s cash flow profile and...

General Dynamics has delivered a 116.0% return over the past 5 years, yet current valuation work suggests the stock may still trade at a discount to its intrinsic value. With fresh contract wins and recent share gains, the key issue for investors is how much of that story is already in the US$380.96 share price. The 116.0% 5 year return signals that General Dynamics has already created substantial value for shareholders, so any further upside may depend on how reliable the current cash flow...

Sarepta Therapeutics (SRPT) is back in focus after the board appointed Michael Severino, M.D., as chief executive and director, with his tenure beginning July 28, 2026, following Douglas Ingram’s departure. See our latest analysis for Sarepta Therapeutics. Despite the leadership change and the recent shelf registration, Sarepta Therapeutics’ 1-day share price return of 0.68% comes after a year-to-date share price decline of 27.10% and a 5-year total shareholder return decline of 76.99%, which...

Mirion Technologies stock was slightly in the red by early afternoon on Wednesday, down about 1.7% near US$14.30 after a tough three months that left shares lower by more than 25%. The market reaction looks cautious, yet the headline from this earnings print is clear. The earnings report put a spotlight on margins and cash generation, with adjusted earnings before interest, tax, depreciation and amortisation expanding and adjusted free cash flow hitting one of the strongest first half...

Skyworks Solutions stock barely moved at all in regular trading, sitting near US$61 after drifting only 0.03% lower, even though the underlying story is far from flat. The company just printed Q3 revenue of about US$935 million with non GAAP earnings per share of US$1.08, both hovering above management’s own midpoint. That is the short term snapshot. The bigger story for you is profit pressure. Gross margin around 45% and operating margin near 19% sit inside a multi quarter squeeze, just as...

Bloom Energy stock is roaring higher today, up about 27% intraday, after a bruising few months for shareholders. The market is treating this as a clean reset on the story. The question is whether that surge reflects genuine earnings power or just excitement about artificial intelligence driven power demand. The headline is simple. Bloom Energy just delivered its first quarter above US$1b in revenue, with Q2 sales of US$1.065b and strong profitability to match. The market is cheering the...

In recent months, Enovis has faced ongoing annual sales declines and weakening returns on capital, suggesting its current growth initiatives are not delivering the intended operational benefits. This erosion of previously reliable profit streams points to deeper operational challenges that may be reducing the effectiveness of the company’s business model and capital deployment. We’ll now examine how Enovis’ operational challenges and sales declines might alter the company’s previously...

Lowe's Companies (LOW) heads toward its August 19, 2026 earnings release with analysts expecting earnings per share to decline year over year, while quarterly revenue is projected to be higher and the stock holds a Zacks Rank #4 (Sell). See our latest analysis for Lowe's Companies. Lowe's Companies' share price of $215.68 reflects a mixed picture, with a 7 day share price return of 5.54% but a year to date share price return down 12.64%. The 1 year total shareholder return is down 3.22% and...

It's been a good week for Zurn Elkay Water Solutions Corporation ( NYSE:ZWS ) shareholders, because the company has...

Abbott Laboratories recently reported second-quarter 2026 results showing sales rising to US$12,593 million from US$11,142 million a year earlier, while net income fell to US$928 million and diluted EPS from continuing operations slipped to US$0.53 from US$1.01. At the same time, Abbott is strengthening its medical device and diagnostics portfolio with a large real-world TriClip heart valve study and ongoing expansion in diabetes and oncology testing, which could reshape how investors view...